deucravacitinib psoriasis
Selected indexed studies
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. (J Am Acad Dermatol, 2023) [PMID:35820547]
- Deucravacitinib in the treatment of psoriasis. (J Dermatolog Treat, 2023) [PMID:36453809]
- Deucravacitinib in moderate-to-severe psoriasis. (Immunotherapy, 2022) [PMID:36373503]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. (2023) pubmed
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. (2023) pubmed
- Deucravacitinib in the treatment of psoriasis. (2023) pubmed
- Deucravacitinib in moderate-to-severe psoriasis. (2022) pubmed
- Deucravacitinib for plaque psoriasis. (2024) pubmed
- Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. (2025) pubmed
- Deucravacitinib: moderate-to-severe plaque psoriasis preventable? (2024) pubmed
- Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis. (2024) pubmed
- A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel. (2025) pubmed
- Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials. (2025) pubmed